2013
DOI: 10.1161/circinterventions.113.000283
|View full text |Cite
|
Sign up to set email alerts
|

First Experience With Implantation of a Percutaneous Right Ventricular Impella Right Side Percutaneous Support Device as a Bridge to Recovery in Acute Right Ventricular Infarction Complicated by Cardiogenic Shock in the United States

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0
1

Year Published

2014
2014
2020
2020

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 21 publications
(9 citation statements)
references
References 4 publications
0
8
0
1
Order By: Relevance
“…First reported by Margey et al , the Impella RP is a minimally invasive RVAD that has been developed particularly to assist the failing right heart. The FDA‐approved Impella RP system is composed of a microaxial pump including a drive motor and an impeller (Fig.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…First reported by Margey et al , the Impella RP is a minimally invasive RVAD that has been developed particularly to assist the failing right heart. The FDA‐approved Impella RP system is composed of a microaxial pump including a drive motor and an impeller (Fig.…”
Section: Discussionmentioning
confidence: 99%
“…The TandemHeart ® (CardiacAssist, Pittsburgh, PA), a centrifugal flow pump, has been used for right‐sided support with an inflow cannula placed in the right atrium (RA) and an outflow cannula in the main pulmonary artery (PA) with one (if not both) of these via femoral venous access . The Impella RP (Abiomed, Danvers, MA), an axial flow pump, has also been developed for right‐sided support and is also inserted via femoral access .…”
Section: Introductionmentioning
confidence: 99%
“…Successful application of the Impella RP in four RHF patients has been reported. 27,2829 The results of the recently finished Canadian/European clinical trial was presented at the 2012 American College of Cardiology meeting, 30 but the data has not been formally published yet. A U.S. clinical trial is currently ongoing to test the Impella RP device.…”
Section: Discussionmentioning
confidence: 99%
“…One of these is the Impella RP, which is a percutaeneous device that has FDA approval for Humanitarian Device Exemption for implantation of up to 14 days in patients with acute right heart failure. It is the first axial flow catheter designed to support the RV 98 99. The RECOVER RIGHT trial was recently published and confirmed the haemodynamic efficacy and safety of the Impella RP 99.…”
Section: Future Perspectivesmentioning
confidence: 98%